Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research
Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services (www.oncodesign-services.com), a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink™ technology for preclinical services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424538240/en/
AbYlink™ is a regio-selective bioconjugation technology ideally suited for preparing conjugates for use in therapeutic and non-invasive diagnostic applications. Oncodesign Services will use this cutting-edge technology to prepare antibody chelator conjugates for use in preclinical studies to gain insights into the predictive effectiveness of novel treatment approaches in Molecular Radiotherapy, and particularly Radioimmunotherapy in the context of cancer. A joint poster will be presented at the AACR Annual Meeting 2025 to demonstrate the use of the non-invasive technology in Radioimmunotherapy, targeting animal models bearing HER2+ tumors.
“We have demonstrated the effectiveness of this powerful technology to rapidly and covalently conjugate any off-the-shelf antibody in a single step with an imaging agent. Our strategic collaboration with Oncodesign Services allows broader access to and usage of non-invasive imaging applications and provides an innovative solution to biotech and pharma partners to integrate imagery in the development of new antibody- and ADC-based therapeutics,” commented Frédéric Lévy, Chief Scientific Officer at Debiopharm.
Aidan Synnott, CEO of Oncodesign Services, said, “We are pleased to integrate this cutting-edge technology into our portfolio for our clients. The AbYlink™ technology gives the advantage of generating reproducible batches of bioconjugated antibodies and ADCs that secure specificity and efficacy of targeted radiotherapy.”
About AbYlink™
AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads.
About Debiopharm Research & Manufacturing
Debiopharm Research & Manufacturing manufactures treatments for prostate cancer, breast cancer and precocious puberty, namely at its Martigny facility, where it employs two hundred people. It is a subsidiary of the pharmaceutical company Debiopharm, headquartered in Lausanne, Switzerland. Debiopharm is an innovative company, devoting over 90% of its resources to innovation and the development of new drugs. Its mission is to develop innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit: www.debiopharm.com
Follow us on LinkedIn https://www.linkedin.com/company/debiopharminternational/
About Oncodesign Services
Oncodesign Services is a contract research organization specializing in drug discovery and preclinical development. The company works with global biopharma partners to advance therapies in oncology, inflammation and infectious diseases through integrated services in protein sciences, structural biology, medicinal chemistry, pharmaco-imaging, DMPK and in vivo/in vitro pharmacology. Oncodesign Services has European facilities in France and the Netherlands.
More information on the website www.oncodesign-services.com
Follow us on LinkedIn https://www.linkedin.com/company/oncodesign/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424538240/en/
Contacts
Debiopharm Research & Manufacturing Contact:
Dawn Bonine – Head of Communications
Dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
Oncodesign Services Contact:
Nathalie Dubois – Marketing Manager
comms@oncodesign-services.com
Tel.: +33 (0)3 80 78 82 60
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smart Communications Announces Acquisition of Joisto24.4.2025 16:45:00 EEST | Press release
Smart CommunicationsTM, the leading cloud-based platform for enterprise customer communications, today announces it has acquired Joisto, a cloud data archive company. As a result, customers will now have the ability to seamlessly store, manage and retrieve digital records and documents, while meeting the stringent requirements for data retention that govern regulated industries worldwide. “We’re delighted to incorporate Joisto’s deep expertise in cloud archival into Smart Communications,” said Leigh Segall, CEO of Smart Communications. “Our leading Conversation Cloud Platform already enables our customers to manage sophisticated customer conversations at tremendous scale. With the addition of Joisto, we will extend these capabilities to meet an increasing need for regulatory-compliant and readily accessible storage of these conversations in the cloud. Together we will support customers worldwide as they continue their journey to modernize and transform customer conversations.” Joisto’s
Rimini Street Appoints Joe Locandro as EVP and Chief Information Officer to Lead Global IT Strategy24.4.2025 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Joe Locandro as executive vice president (EVP) and chief information officer (CIO). In this role, Locandro will lead Rimini Street’s global IT operations, oversee enterprise systems strategy and drive technology innovation initiatives in support of Rimini Street’s continued growth and client success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424168093/en/ Rimini Street Appoints Joe Locandro as EVP and Chief Information Officer to Lead Global IT Strategy Deep Technology Leadership Across Range of Industries and Regions Locandro brings more than 25 years of international leadership experience across sectors including energy, aviation, utilities, construction, and entertain
Boomi World 2025: Accelerating What’s Next in AI, Integration, and the Connected Enterprise24.4.2025 16:00:00 EEST | Press release
Boomi™, the intelligent integration and automation leader, is excited to announce that Boomi World 2025 will be held May 12-15, 2025, in Dallas, Texas. This premier event will showcase the latest advancements in AI-driven integration and automation, bringing together industry leaders, innovative thinkers, and Boomi customers and partners to explore how these technologies are reshaping the future. Attendees will gain valuable insights on how to break down silos, streamline operations, and make informed, data-driven decisions through a series of keynote sessions, breakout discussions, and hands-on training opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424969941/en/ Boomi World 2025: Accelerating What’s Next in AI, Integration, and the Connected Enterprise Emceed by technology industry veteran and correspondent Lisa Martin, Boomi World 2025 will feature esteemed speakers, including: Tara Davis-Woodhall and Hu
Bregal Milestone and Ridango Announce the Acquisition of uTrack Software Solutions24.4.2025 16:00:00 EEST | Press release
Bregal Milestone, a leading European software growth private equity firm, is pleased to share that, since announcing its strategic growth investment in Swedish global provider of mission-critical public transportation software Ridango AS (“Ridango”) last month, it has also agreed to acquire uTrack Software Solutions (“uTrack”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424607486/en/ Eamonn Hughes and Erki Lipre Founded in 2011 by Eamonn Hughes and Conor Gildea, uTrack is a Dublin-headquartered software company providing a public transport data platform with a real-time analysis and predictive engine that feeds a suite of software services that annually supports nearly 3 billion passengers, over 5 million app users, 150,000+ drivers and 73,000+ vehicles. uTrack‘s clients include some of the largest urban bus, intercity coach, and school transport providers across Ireland, the UK, and North America. The company’s suite
Curiosity Cube 2025: Merck’s Mobile Science Labs Tour Globally to Bring STEM Education to Students24.4.2025 15:00:00 EEST | Press release
Merck, a leading science and technology company, today launched its global 2025 Curiosity Cube tour in Darmstadt, Germany. The solar-powered mobile science labs will bring hands-on STEM (science, technology, engineering and mathematics) experiences to students across Europe, North America, and for the first time, Africa. In 2025, the tour aims to reach 60,000 students worldwide. The initiative underscores Merck's commitment to inspiring enthusiasm for science and technology. Merck today also opened its Curiosity Labs™ STEM Center in Darmstadt with 11 interactive science lessons to complement the Curiosity Cube experience for local students year-round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424271266/en/ The mobile science labs tour Europe, North America and for the first time, Africa. “With technological advances and scientific breakthroughs reshaping the world, it has never been more important to inspire early in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom